Please check your internet connection and try again.
# Hyoscine butylbromide
## Overview
Hyoscine butylbromide (Scopolamine butylbromide) is a peripherally acting antispasmodic agent. Unlike hyoscine hydrobromide, it is a quaternary ammonium derivative and does not readily cross the blood-brain barrier, resulting in minimal central nervous system effects.
## Primary Indications
* Acute gastrointestinal, biliary, and genitourinary smooth muscle spasms.
* Gastrointestinal diagnostic procedures (e.g., endoscopy/radiology).
* Palliative care (management of "death rattle" or excessive respiratory secretions, though evidence is limited compared to glycopyrrolate/atropine).
## Adult Dosing
* **Oral:** 10 mg to 20 mg three to four times daily. Maximum: 100 mg/day.
* **Intramuscular/Intravenous/Subcutaneous:** 20 mg as a single dose, repeated every 30 minutes if necessary (maximum 100 mg/day).
* **Dosing Note:** Exact dosing frequencies for specific conditions may vary by local institutional protocol.
## Pediatric Dosing
* **Children (6–12 years):** 10 mg orally three times daily.
* **Children/Infants:** Safety and efficacy have not been firmly established for all age groups. Use is generally off-label and requires pediatrician oversight. Dosing is highly protocol-dependent; consult institutional guidelines.
## Dose Adjustments
* **Renal/Hepatic Impairment:** No specific guidelines; use with caution due to lack of pharmacokinetic data.
* **Elderly:** Reduce dose or increase interval if cognitive impairment or urinary retention risk exists, despite limited CNS penetration.
## Contraindications
* Myasthenia gravis.
* Mechanical intestinal obstruction or paralytic ileus.
* Megacolon.
* Narrow-angle glaucoma.
* Tachycardia/Tachyarrhythmias.
* Prostatic hypertrophy (with urinary retention).
## Adverse Effects
* **Common:** Dry mouth, tachycardia, blurred vision (mydriasis), constipation.
* **Serious:** Anaphylaxis (rare), urinary retention, acute angle-closure glaucoma, tachycardia-induced myocardial ischemia.
## Key Drug Interactions
* **Anticholinergics:** Synergistic effects (e.g., increased dry mouth, urinary retention) with tricyclic antidepressants, antihistamines, and antipsychotics.
* **Metoclopramide/Prokinetics:** Antagonistic effects on GI motility; avoid concomitant use unless strictly indicated.
## Monitoring
* Monitor heart rate (risk of tachycardia).
* Assess for urinary output/retention.
* Monitor vision (potential for blurred vision/glaucoma).
* Evaluate symptomatic relief of spasms versus persistence of underlying pathology.
## Clinical Pearls
* **Absence of CNS effects:** Hyoscine butylbromide is preferred over hyoscine hydrobromide when peripheral antispasmodic effects are needed without sedation.
* **Palliative Care:** Often utilized off-label for sub-cutaneous infusion in palliative settings, but clinicians should verify local compatibility with other medications (e.g., morphine or midazolam).
* **Not a Painkiller:** It does not possess significant analgesic properties; ensure concomitant analgesia is provided for painful abdominal spasms.
***
**Educational Disclaimer:** This information is for educational purposes only. Drug dosing, contraindications, and interactions should be verified against current institutional protocols, local regulatory prescribing information (e.g., SmPC or FDA labels), and clinical judgment before administration.
